Literature DB >> 6995292

6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.

C P Quilley, J C McGiff, W H Lee, F F Sun, P Y Wong.   

Abstract

Hepatic metabolism of prostacyclin (PGI2) results in the formation of several biologically inactive lipids and one stable product that has the same chromatographic and biological properties as authentic 6-keto PGE1. Both prostaglandins, 6-keto PGE1 and PGI2, have comparable potency in their antiaggregatory and disaggregatory effects on platelets. They contract the superfused rat stomach strip but differ in their effects on the bovine coronary artery, which is contracted by 6-keto PGE1 but relaxed by PGI2. Further, 6-keto PGE1 is considerably more stable than PGI2. Thus, 6-keto PGE1 could account for some of the prolonged effects occasionally seen with PGI2.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995292     DOI: 10.1161/01.hyp.2.4.524

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  3 in total

1.  The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.

Authors:  K Schrör; H Darius; R Matzky; R Ohlendorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-06       Impact factor: 3.000

2.  6-Keto-prostaglandin E1-stimulated bone resorption in organ culture.

Authors:  F E Dewhirst
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

3.  Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung.

Authors:  C N Berry; R J Griffiths; J R Hoult; P K Moore; G W Taylor
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.